Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 12, pp 3297–3304 | Cite as

Quercetin Attenuates Adhesion Molecule Expression in Intestinal Microvascular Endothelial Cells by Modulating Multiple Pathways

  • Yifei Bian
  • Ping Liu
  • Jia Zhong
  • Yusheng Hu
  • Shen Zhuang
  • Kai Fan
  • Zhongjie LiuEmail author
Original Article

Abstract

Background

In inflammatory bowel disease, activation of microvascular endothelial cells and adhesion of immune cells are required for the initiation and maintenance of inflammation. We evaluated the effects and mechanisms of quercetin, a flavone identified in a wide variety of dietary sources, in LPS-induced rat intestinal microvascular endothelial cells (RIMVECs).

Methods

RIMVECs were pretreated with quercetin of various concentrations (20, 40 and 80 μM) followed by LPS (10 μg/ml) stimulation. ELISA was used to examine protein levels of intercellular adhesion molecules-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the supernatant. Protein levels of Toll-like receptor 4 (TLR4), nuclear transcription factor kappa B (NF-κB) p65, inhibitors of NF-κB (IκB-α), extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK) p38 and signal transducer and activator of transcription (STAT) in cells were measured by Western blot.

Results

Quercetin significantly suppressed protein levels of ICAM-1 and VCAM-1 induced by LPS. Quercetin also inhibited TLR4 expression, NF-κB p65, ERK, JNK and STAT phosphorylation and decreased IκB-α degradation. Moreover, the MAPK p38 signal does not contribute to the anti-inflammatory effects on RIMVECs, although LPS significantly increases its phosphorylation.

Conclusions

These results indicate that quercetin may have an anti-inflammatory effect by inhibiting expression of ICAM-1 and VCAM-1 in RIMVECs by suppressing TLR4, NF-κB, ERK, JNK and STAT but not the p38 signaling pathway.

Keywords

Quercetin IBD Rat intestinal microvascular endothelial cells (RIMVECs) Adhesion molecules Signaling pathway 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant no. 31472228).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol. 2016;11:127–148.CrossRefGoogle Scholar
  2. 2.
    Saijo HN, Tatsumi S, Arihiro T, et al. Microangiopathy triggers, and inducible nitric oxide synthase exacerbates dextran sulfate sodium-induced colitis. Lab Invest. 2015;95:728–748.CrossRefGoogle Scholar
  3. 3.
    Binion DG, West GA, Ina K, Ziats NP, Emancipator SN, Fiocchi C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997;112:1895–1907.CrossRefGoogle Scholar
  4. 4.
    Israely E. Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. Dev Cell. 2013;26:204–219.CrossRefGoogle Scholar
  5. 5.
    Aird WC. Phenotypic heterogeneity of the endothelium. Circ Res. 2007;100:158–173.CrossRefGoogle Scholar
  6. 6.
    Daniele F, Francesco P. What is the role of cytokines and chemokines in IBD? Inflamm Bowel Dis. 2008;2:S117.Google Scholar
  7. 7.
    Francescone R, Hou V, Grivennikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015;21:409–418.CrossRefGoogle Scholar
  8. 8.
    Moldoveanu AC, Diculescu M, Braticevici CF. Cytokines in inflammatory bowel disease. Scand J Gastroenterol. 2015;53:118–127.Google Scholar
  9. 9.
    Itzkowitz SH, Yio X. Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:7.CrossRefGoogle Scholar
  10. 10.
    Boer NKD, Bodegraven AAV, Jharap B, De GP, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:686–694.CrossRefGoogle Scholar
  11. 11.
    Pérezcano FJ, Castell M. Flavonoids, inflammation and immune system. Nutrients. 2016;8:659–662.CrossRefGoogle Scholar
  12. 12.
    Yao L, Yao JC, Han J, et al. Quercetin, inflammation and immunity. Nutrients. 2016;8:167.CrossRefGoogle Scholar
  13. 13.
    Chen CC, Chow MP, Huang WC, Lin YC, Chang YJ. Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: structure-activity relationships. Mol Pharmacol. 2004;66:683–693.CrossRefGoogle Scholar
  14. 14.
    Manjeet KR, Ghosh B. Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-α production in murine macrophages. Int J Immunopharmacol. 1999;21:435–443.CrossRefGoogle Scholar
  15. 15.
    Chang YC, Tsai MH, Sheu WH, Hsieh SC, Chiang AN. The therapeutic potential and mechanisms of action of quercetin in relation to lipopolysaccharide-induced sepsis in vitro and in vivo. PLoS ONE. 2013;8:e80744.CrossRefGoogle Scholar
  16. 16.
    Crespo I, Garcíamediavilla MV, Gutiérrez B, Sánchezcampos S, Tuñón MJ, Gonzálezgallego J. A comparison of the effects of kaempferol and quercetin on cytokine-induced pro-inflammatory status of cultured human endothelial cells. Br J Nutr. 2008;100:968–976.CrossRefGoogle Scholar
  17. 17.
    Dodda D, Chhajed R, Mishra J. Protective effect of quercetin against acetic acid induced inflammatory bowel disease (IBD) like symptoms in rats: Possible morphological and biochemical alterations. Pharmacol Rep. 2014;66:169–173.CrossRefGoogle Scholar
  18. 18.
    Duan H, Zhang Y, Xu J, et al. Effect of anemonin on NO, ET-1 and ICAM-1 production in rat intestinal microvascular endothelial cells. J Ethnopharmacol. 2006;104:362–366.CrossRefGoogle Scholar
  19. 19.
    Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets. 2011;11:451–466.CrossRefGoogle Scholar
  20. 20.
    Kasper J, Hermanns MI, Cavelius C, et al. The role of the intestinal microvasculature in inflammatory bowel disease: studies with a modified Caco-2 model including endothelial cells resembling the intestinal barrier in vitro. Int J Nanomed. 2016;11:6353–6364.CrossRefGoogle Scholar
  21. 21.
    Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434.CrossRefGoogle Scholar
  22. 22.
    Seaman S, Stevens J, Mi YY, Logsdon D, Graffcherry C, Croix BS. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11:539–554.CrossRefGoogle Scholar
  23. 23.
    Müller AM, Hermanns MI, Cronen C, Kirkpatrick CJ. Comparative study of adhesion molecule expression in cultured human macro- and microvascular endothelial cells. Exp Mol Pathol. 2002;73:171–180.CrossRefGoogle Scholar
  24. 24.
    Hu YS, Lin RY, Bian YF, Fan K, Liu ZJ. Protective effect of Kushenlu on lipopolysaccharide-induced small intestinal inflammation in rats. Int J Pharmacol. 2017;13:473–480.CrossRefGoogle Scholar
  25. 25.
    Suo Z, Liu Y, Ferreri M, et al. Impact of matrine on inflammation related factors in rat intestinal microvascular endothelial cells. J Ethnopharmacol. 2009;125:404–409.CrossRefGoogle Scholar
  26. 26.
    Binion DG, Rafiee P. Is inflammatory bowel disease a vascular disease? Targeting angiogenesis improves chronic inflammation in inflammatory bowel disease. Gastroenterology. 2009;136:400–403.CrossRefGoogle Scholar
  27. 27.
    Choo BK, Roh SS. Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines. Exp Ther Med. 2013;6:663–670.CrossRefGoogle Scholar
  28. 28.
    Bhaskar S, Sudhakaran PR, Helen A. Quercetin attenuates atherosclerotic inflammation and adhesion molecule expression by modulating TLR-NF-κB signaling pathway. Cell Immunol. 2016;310:131–140.CrossRefGoogle Scholar
  29. 29.
    Jobin C, Hellerbrand C, Licato LL, Brenner DA, Sartor RB. Mediation by NF-κB of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut. 1998;42:779–787.CrossRefGoogle Scholar
  30. 30.
    Li Z, Zhang DK, Yi WQ, Ouyang Q, Chen YQ, Gan HT. NF-kappaB p65 antisense oligonucleotides may serve as a novel molecular approach for the treatment of patients with ulcerative colitis. Arch Med Res. 2008;39:729–734.CrossRefGoogle Scholar
  31. 31.
    Comalada M, Camuesco D, Sierra S, et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-κB pathway. Eur J Immunol. 2005;35:584–592.CrossRefGoogle Scholar
  32. 32.
    Cui L, Feng L, Zhang ZH, Jia XB. The anti-inflammation effect of baicalin on experimental colitis through inhibiting TLR4/NF-κB pathway activation. Int Immunopharmacol. 2014;23:294–303.CrossRefGoogle Scholar
  33. 33.
    Jang J, Ha JH, Chung SI, Yoon Y. Β-catenin regulates NF-κB activity and inflammatory cytokine expression in bronchial epithelial cells treated with lipopolysaccharide. Int J Mol Med. 2014;34:632–638.CrossRefGoogle Scholar
  34. 34.
    Lucas K, Maes M. Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013;48:190–204.CrossRefGoogle Scholar
  35. 35.
    Akira S, Hoshino K, Kaisho T. The role of Toll-like receptors and MyD88 in innate immune responses. J Endotoxin Res. 2000;6:383–387.CrossRefGoogle Scholar
  36. 36.
    Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999;11:115–122.CrossRefGoogle Scholar
  37. 37.
    Chen C, Chen YH, Lin WW. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology. 1999;97:124–129.CrossRefGoogle Scholar
  38. 38.
    Liu W, Liu Y, Wang Z, Yu T, Lu Q, Chen H. Suppression of MAPK and NF-κ B pathways by schisandrin B contributes to attenuation of DSS-induced mice model of inflammatory bowel disease. Pharmazie. 2015;70:598–603.PubMedGoogle Scholar
  39. 39.
    Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66–82.CrossRefGoogle Scholar
  40. 40.
    Endale M, Park SC, Kim S, et al. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells. Immunobiology. 2013;218:1452–1467.CrossRefGoogle Scholar
  41. 41.
    Rasjad IM, Satuman K, Retty R, Malik SG. Quercetin suppresses inflammation by reducing ERK1/2 phosphorylation and NF kappa B activation in leptin-induced human umbilical vein endothelial cells (HUVECs). BMC Res Notes. 2013;6:1–8.CrossRefGoogle Scholar
  42. 42.
    Ying BW, Yang T, Song XB, et al. Quercetin inhibits IL-1 beta-induced ICAM-1 expression in pulmonary epithelial cell line A549 through the MAPK pathways. Mol Biol Rep. 2009;36:1825–1832.CrossRefGoogle Scholar
  43. 43.
    Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL, Wolff RK. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog. 2013;52:155–166.CrossRefGoogle Scholar
  44. 44.
    Nunes C, Almeida L, Barbosa RM, Laranjinha J. Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation. Food Funct. 2017;8:387.CrossRefGoogle Scholar
  45. 45.
    Cho YS, Chan HK, Ha TS, Ahn HY. Inhibition of NF-kB and STAT3 by quercetin with suppression of adhesion molecule expression in vascular endothelial cells. Farmacia. 2016;64:668–673.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yifei Bian
    • 1
  • Ping Liu
    • 1
  • Jia Zhong
    • 1
  • Yusheng Hu
    • 1
  • Shen Zhuang
    • 1
  • Kai Fan
    • 1
  • Zhongjie Liu
    • 1
    Email author
  1. 1.Division of Traditional Chinese Veterinary Medicine, College of Veterinary MedicineChina Agricultural UniversityBeijingPeople’s Republic of China

Personalised recommendations